London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells
University of Auckland data
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021 https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1).
The in vitro data show effectiveness of the Company's lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand, together with the more commonly used commercially available cell lines. 3D spheroids are aggregations of tumour cells that more closely reflect the structure of tumours in patients. In these in vitro experiments, SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously announced by the Company in another academic centre.
Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives.
Dr Huw Jones, CEO of Evgen, commented: "This careful and well-controlled set of experiments by Dr Leung and Prof Baguley confirm work communicated to us by Dr Festuccia of the University of L'Aquila, Abruzzo, Italy and are now available through the rapid publication BioRxIV. We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal. They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.''
Actually posting the link: https://vimeo.com/556541905/fa8f27c9a8
Have a listen to this interview with the CEO of Juvenescence from a few months ago. In it he talks about $$billions in revenue for the sulforaphane based product they will be releasing which has a non-medical form of SFX-01 from Evgen as it's active ingredient. Product release currently expected 4/23.
All due in the next 3 months or so. Would be nice to think we can maintain an upwards SP trend in this time. Then the fully-funded trial will be initiated early next year. Re-rate to somewhere near a market comparable value you would think could well happen at some point as well. With the £10m+ cash in the bank the enterprise value here is a measily £6m lol lol.
(Also lets not forget we have $10.25m in milestone payments due over the next 18 months from Juvlife followed by royalties on sales)
Next step on Glioma is pre-IND meeting followed by full IND submission (then hopefully FDA approval).
ODD designation should help tremendously.
Rerated soon , Cash over £12 million "This is part of a wider strategy to access the U.S. market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering," Evgen Chief Executive Huw..... Wake up call soon IMO
Gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering." Update soon FDA approval expected..
As I posted on the 26th August
"easy- I'm working on the basis that kight is the only major buyer, he is building a position from between 5 to 6 p. He is done for now and the price will drift back to the lows 5p over the next week or so. Buy around 5.2p and sell around 6.4p. Follow this strategy and you will make money, don't buy and hold"
Admittedly I got my upside wrong when the price was ramped up by the market makers to suck in more unsuspecting saps, but the trend has now re established itself.
Kight will be loading up again at around 5.25p.
Money munch "An example of a negatively biased blinkered view 27th August...Ho ho ho ho ho.... ;-)" 3rd Sept post. Wrong again mate.
One has to be a bit patient …
When the big guys have finished buying the impatient holders we should see a steady rise , IMO
Will this ever go back up? Seems absolutely no interest in this share!
Everyone to their own trades , easyp :-)
Having sold some at 7.8p I did buy more 24hrs later give or take at 6.79. Only a penny difference but you can make and lose money by trading the waves in small volatile biotechs. My overall position still a little in the blue today but I lost money some months ago when I bailed out. It is one way of many trading strategies which board members will be familiar with, each to their own.
More importantly, I think there is the chance of more good scientific news here so willing to risk some of my pension savings on EVG.
Also called pump and dump...……………..
It's called a shake-out of small short-term PI traders, which the MM's are fully aware piled in at the end of last week. A very easy way to collect stock for longer-term accumulators such as Kight.
What on earth is going on here?
I realise that Nolupus, but the speed of granting Orphan status does seem extraordinary, and so i'm hoping for a partner with influence, and we know how excited Huw was with the initial pre-clinical data from University L'Aquila , which has now also been reproduced by University of Auckland, and so obviously compelling for a speedy decision from the FDA which also might be enough to garner interest or galvanise current interest from a potential suitor. Gl ;-)
13/7/21
Dr Huw Jones, CEO of Evgen, commented: "Given the progress with our glioma programme and our intent to commence trials in 2022, we are seeking Orphan Drug status to maximise our intellectual property protection, commercial potential and partner appeal in this devastating disease. The incentives offered by OD designation mean that rare diseases like glioblastoma are more likely to be researched in the clinic. "
MM,
The FDA could’nt care less about a partner etc …
Can't help thinking there could be a significant reason for the speed the FDA granted Orphan Drug designation, especially during the holiday season when you'd expect things to go slow......here's hoping a commercial partner in the pipeline is the reason. Gla ;-)
Turning now …
Let’s see where we close the day ..
Was always going to be dragged down to inflection point by mm's, especially as few shares in public hands, and theirs buyers around. This will turn
We knew about the Orphan Drug Designation several hours before the RNS and so no doubt some jumped in and out again with their profits, the sp was also at sub 5p a month or so ago and so plenty banking profits at 8p plus who've bought in on the lows and probably a few pi's who had been sitting in the red since the 8p placing and Covid news......all part of the trading process when shares move UP.....and we're now ready for the next move UP imho, the share float is becoming tight with Mr Kight and co buying and there's plenty of material news from the rest of the pipeline that could drop at anytime and drive the sp back to double figures. Gla holders. :-)
At a guess its traders who got the nod news was coming they made a nice profit
welcome to AIM. Is it any wonder why companies seek to list elsewhere as soon as they can?